Richard L Momparler

Summary

Country: Canada

Publications

  1. pmc Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
    Annie Hurtubise
    Departement de Pharmacologie, Universite de Montreal, Centre de Recherche Pediatrique, and Service d hématologie oncologie, Hopital Sainte Justine, 3175 Cote Sainte Catherine, Montreal, Quebec, H3T 1C5, Canada
    Cancer Cell Int 8:16. 2008
  2. doi Targeting of cancer stem cells by inhibitors of DNA and histone methylation
    Richard L Momparler
    Universite de Montreal, Centre de Recherche, Departement de Pharmacologie, CHU Saint Justine, Montreal, Quebec, Canada
    Expert Opin Investig Drugs 24:1031-43. 2015
  3. pmc A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
    Richard L Momparler
    Departement de Pharmacologie, Service d hématologie et oncologie, Centre de Recherche, CHU Saint Justine, Universite de Montreal, Montreal, Quebec H3T 1C5, Canada
    Pharmaceuticals (Basel) 5:875-81. 2012
  4. doi Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
    Richard L Momparler
    D partement de Pharmacologie, Universit de Montr al and Service d h matologie oncologie, CHU Saint Justine, 3175 Cote Sainte Catherine, Montr al QC H3T 1C5, Canada
    Exp Hematol Oncol 2:20. 2013
  5. pmc Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine)
    Richard L Momparler
    Departement de Pharmacologie, Centre de recherche du CHU Sainte Justine, Universite de Montreal, Montreal, QC, Canada
    Front Oncol 3:188. 2013
  6. doi Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
    Richard L Momparler
    Departement de Pharmacologie, Universite de Montreal, Canada
    Leuk Res 37:980-4. 2013
  7. pmc Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
    Metin Karahoca
    Departement de Pharmacologie, Universite de Montreal, Montreal, Quebec, Canada
    Clin Epigenetics 5:3. 2013
  8. doi Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
    Richard L Momparler
    Departement de Pharmacologie, Universite de Montreal, Montreal, Quebec, Canada
    Leuk Res 36:1049-54. 2012
  9. ncbi Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)
    Richard L Momparler
    Departement de Pharmacologie, Université de Montréal and Centre de recherche pédiatrique, Hopital Ste Justine, 3175 Cote Sainte Catherine, Montreal, Quebec H3T 1C5, Canada
    Semin Oncol 32:443-51. 2005
  10. ncbi Pharmacology of 5-Aza-2'-deoxycytidine (decitabine)
    Richard L Momparler
    Centre de Recherche, Hopital Sainte Justine, Montreal, Quebec, Canada
    Semin Hematol 42:S9-16. 2005

Collaborators

Detail Information

Publications27

  1. pmc Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
    Annie Hurtubise
    Departement de Pharmacologie, Universite de Montreal, Centre de Recherche Pediatrique, and Service d hématologie oncologie, Hopital Sainte Justine, 3175 Cote Sainte Catherine, Montreal, Quebec, H3T 1C5, Canada
    Cancer Cell Int 8:16. 2008
    ..These epigenetic changes can be reversed by using 5-aza-2'-deoxycytidine (5AZA-CdR), a potent inhibitor of DNA methylation, in combination with an inhibitor of histone deacetylase (HDAC)...
  2. doi Targeting of cancer stem cells by inhibitors of DNA and histone methylation
    Richard L Momparler
    Universite de Montreal, Centre de Recherche, Departement de Pharmacologie, CHU Saint Justine, Montreal, Quebec, Canada
    Expert Opin Investig Drugs 24:1031-43. 2015
    ..It is possible to reverse this 'double lock' mechanism using a combination of inhibitors of EZH2 and DNA methylation (5-aza-2'-deoxycytidine), which exhibits remarkable synergistic antineoplastic activity in preclinical studies...
  3. pmc A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
    Richard L Momparler
    Departement de Pharmacologie, Service d hématologie et oncologie, Centre de Recherche, CHU Saint Justine, Universite de Montreal, Montreal, Quebec H3T 1C5, Canada
    Pharmaceuticals (Basel) 5:875-81. 2012
    ..These observations should be taken into consideration in the design of new clinical trials using 5-AZA-CdR or 5-AC in patients with MDS and AML. ..
  4. doi Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
    Richard L Momparler
    D partement de Pharmacologie, Universit de Montr al and Service d h matologie oncologie, CHU Saint Justine, 3175 Cote Sainte Catherine, Montr al QC H3T 1C5, Canada
    Exp Hematol Oncol 2:20. 2013
    ..Several approaches are proposed in this commentary to overcome these impediments with the goal of increasing the effectiveness of cytarabine for the treatment of acute myeloid leukemia...
  5. pmc Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine)
    Richard L Momparler
    Departement de Pharmacologie, Centre de recherche du CHU Sainte Justine, Universite de Montreal, Montreal, QC, Canada
    Front Oncol 3:188. 2013
    ..This delayed action should be taken into consideration in the design and evaluation of clinical studies on DAC. Future research should be directed at finding the optimal dose-schedule of de DAC for the treatment of NSCLC. ..
  6. doi Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
    Richard L Momparler
    Departement de Pharmacologie, Universite de Montreal, Canada
    Leuk Res 37:980-4. 2013
    ....
  7. pmc Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
    Metin Karahoca
    Departement de Pharmacologie, Universite de Montreal, Montreal, Quebec, Canada
    Clin Epigenetics 5:3. 2013
    ..The full chemotherapeutic potential of 5-AZA-CdR to treat cancer merits further clinical investigation and can only be realized when its optimal dose-schedule is determined...
  8. doi Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
    Richard L Momparler
    Departement de Pharmacologie, Universite de Montreal, Montreal, Quebec, Canada
    Leuk Res 36:1049-54. 2012
    ..Our results indicate that 5-AZA-CdR plus DZNep can reactivate target genes that are silenced by two distinct epigenetic mechanisms leading to a loss of the proliferative potential of leukemic cells...
  9. ncbi Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)
    Richard L Momparler
    Departement de Pharmacologie, Université de Montréal and Centre de recherche pédiatrique, Hopital Ste Justine, 3175 Cote Sainte Catherine, Montreal, Quebec H3T 1C5, Canada
    Semin Oncol 32:443-51. 2005
    ..This will require a good understanding of the pharmacology of this analog and its action on both normal and neoplastic cells...
  10. ncbi Pharmacology of 5-Aza-2'-deoxycytidine (decitabine)
    Richard L Momparler
    Centre de Recherche, Hopital Sainte Justine, Montreal, Quebec, Canada
    Semin Hematol 42:S9-16. 2005
    ..Translation of the pharmacology of 5AZA-CdR into therapeutic regimens based on scientific rationale can be used to obtain this objective...
  11. ncbi Cancer epigenetics
    Richard L Momparler
    Département de pharmacology, Universite de Montreal, Centre de Recherche, Hopital Sainte Justine, 3175 Côte Ste Catherine Montreal, Que H3T 1C5, Canada
    Oncogene 22:6479-83. 2003
    ....
  12. ncbi Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells
    Maryse Lemaire
    Department de Pharmacologie, Universite de Montreal, Centre de Recherche Pediatrique, Hopital Sainte Justine, 3175 Cote Sainte Catherine, Montreal, Quebec H3T 1C5, Canada
    Leuk Lymphoma 45:147-54. 2004
    ..We also observed an enhancement of the antineoplastic activity of this combination in mice with L1210 leukemia. These data provide a rationale to investigate 5-AZA-CdR and PB in patients with advanced leukemia...
  13. ncbi Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells
    Sepideh Shaker
    Departement de Pharmacologie, Universite de Montreal, Montreal, Quebec H3T 1C5, Canada
    Oncol Rep 11:1253-6. 2004
    ..5AZA and depsi may be an interesting drug combination to investigate in patients with lymphoma...
  14. ncbi Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells
    Jacynthe Gagnon
    Departement de Pharmacologie, Université de Montréal and Centre de recherche pédiatrique, Hopital Sainte Justine, Montreal, Quebec, Canada
    Anticancer Drugs 14:193-202. 2003
    ..2)..
  15. ncbi Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines
    Annie Hurtubise
    Departement de Pharmacologie, Universite de Montreal, Hopital Sainte Justine, 3175 Cote Sainte Catherine, Montreal, Quebec H3T 1C5, Canada
    Anticancer Drugs 15:161-7. 2004
    ..These results provide a rationale for clinical trials on the combination of 5-AZA-CdR and Taxo in patients with advanced cancer...
  16. ncbi Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells
    Annie Hurtubise
    Departement de Pharmacologie, Centre de Recherche Pediatrique, Service d hématologie oncologie, Hopital Sainte Justine, Universite de Montreal, 3175 Cote Sainte Catherine, H3T 1C5, Montreal, QC, Canada
    Cancer Chemother Pharmacol 58:618-25. 2006
    ..The antineoplastic activity of these agents was evaluated by clonogenic assay and inhibition of DNA synthesis...
  17. ncbi Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells
    Melanie Primeau
    Departement de Pharmacologie, Université de Montréal and Centre de recherche pédiatrique, Hopital Sainte Justine, Montreal, Quebec, Canada
    Int J Cancer 103:177-84. 2003
    ....
  18. pmc Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
    Maryse Lemaire
    Departement de Pharmacologie, Universite de Montreal, Centre de Recherche Pediatrique, Service d hématologie oncologie, Hopital Sainte Justine, 3175 Cote Sainte Catherine, Montreal, Quebec H3T 1C5, Canada
    BMC Cancer 8:128. 2008
    ..Although clinical studies show that DAC has activity against hematological malignancies, the optimal dose-schedule of this epigenetic agent still needs to be established...
  19. ncbi Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia
    Maryse Lemaire
    Departement de Pharmacologie, Universite de Montreal, Montreal, Canada
    Anticancer Drugs 16:301-8. 2005
    ..The probable mechanism of this drug interaction involves inhibition of CD by Zeb and the complementary inhibition of DNA methylation by both agents...
  20. doi Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine
    Maryse Lemaire
    Departement de Pharmacologie, Universite de Montreal, QC, Canada
    Cancer Chemother Pharmacol 63:411-6. 2009
    ..These findings provide a rationale to investigate 5-AZA-CdR in combination with zebularine in patients with advanced leukemia...
  21. ncbi Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells
    Sepideh Shaker
    Centre de Recherche Pediatrique, Hopital Sainte Justine, 3175 Cote Ste Catherine, Montreal, Quebec, Canada H3T 1C5
    Leuk Res 27:437-44. 2003
    ..These results suggest that 5AZA used in combination with HDI may be an interesting chemotherapeutic regimen to investigate in patients with acute myeloid leukemia that is resistant to conventional chemotherapy...
  22. ncbi Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells
    Anne Julie Boivin
    Departement de Pharmacologie, Université de Montréal and Centre de recherche pédiatrique, Hopital Sainte Justine, Montreal, Quebec H3T 1C5, Canada
    Anticancer Drugs 13:869-74. 2002
    ..Also, in a clonogenic assay the combination of these drugs showed a significant synergistic antitumor effect. These results provide a rationale to investigate the combination of 5-AZA-CdR and PB in patients with advanced lung cancer...
  23. ncbi Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine)
    Nuno J Farinha
    Service d hématologie oncologie, Hopital Sainte Justine, Montreal, Quebec H3T 1C5, Canada
    Anticancer Res 24:75-8. 2004
    ..The objective of this study was to determine the concentrations of 5AZA that will re-activate target silent genes in human leukemic cell lines...
  24. doi 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase
    Noel J M Raynal
    Service of Hematology and Oncology, Université de Montréal and Centre de Recherche, CHU Saint Justine, 3175 Ste Catherine Road, Montreal, Quebec, H3T 1C5 Canada
    Leuk Res 35:110-8. 2011
    ..Our preclinical and clinical results provide a strong rationale to further investigate the combination of 5-AZA-CdR and 3-DU for the treatment of advanced ALL...
  25. ncbi Action of troxacitabine on cells transduced with human cytidine deaminase cDNA
    Anne Julie Boivin
    Centre de Recherche, Hopital Sainte Justine, Departement de Pharmacologie, Universite de Montreal, Montreal, Quebec, Canada
    Cancer Invest 22:25-9. 2004
    ..These results suggest that troxacitabine may be an effective antineoplastic agent against tumors with high levels of CD that show drug resistance to cytosine nucleoside analogs...
  26. ncbi Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene
    Christian M Beausejour
    Departement de Pharmacologie, Universite de Montreal, Centre de Recherche Pediatrique, Hopital Ste Justine, Montreal, Que, Canada
    Biochem Biophys Res Commun 293:1478-84. 2002
    ..These findings may further clarify the action of dFdC and the mechanism by which it induces cell death...
  27. doi Antileukemic activity of genistein, a major isoflavone present in soy products
    Noel J M Raynal
    INRS Institut Armand Frappier, Universite du Quebec, Laval, Canada
    J Nat Prod 71:3-7. 2008
    ..Due to the longer half-life of genistein in humans, a soy-enriched diet has the potential to produce plasma levels of this isoflavone in the range of the concentrations used in vitro that produced an antileukemic activity...